weekly_bull_sm

Friday, Oct 26, 2018

News Recap:

HepCBC Annual General Meeting INVITATION TO ALL
We invite everyone to have a say in the direction of HepCBC, a BC-wide patient advocacy group confronting Viral Hepatitis since 1996, through participation in our upcoming Annual General Meeting (AGM) – either in person or online!

7th Annual Liver Forum 2018 in Vancouver!
On October 19th, Volunteers Douglas Laird and Cheryl Reitz of HepCBC attended the exciting 7th Annual Liver Forum 2018 in Vancouver to hear the latest about research and best practices in the areas of hepatitis B (HBV) and C (HCV), Non-Alcoholic Fatty Liver Disease (NAFLD), and the sequelae of all three, including cirrhosis and its complications (hepatic encephalopathy [HE], ascites, autoimmune liver diseases, etc.).

Interleukin IL-22, a new target to inhibit the progression of liver disease
Naglaa Shoukry, Ph. D., and her team have made a significant breakthrough in their research aiming to limit the progression of liver disease. They have characterized the mechanisms of action of type 3 inflammatory cytokines that are produced by the cells of the immune system, which result in a progression of hepatic scarring known as fibrosis.

Does Pharma Try to Influence Patient Advocacy Groups such as HepCBC?
The Globe and Mail published an article on October 22nd by Kelly Grant entitled, “How pharma firms try to use funding to sway patient advocate groups,” which rightly exposes some of the clear dangers inherent in the relationship between industry funders and patient groups.